A5034494289- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Diabetes and associated disorders
- Immunodeficiency and Autoimmune Disorders
- Long-Term Effects of COVID-19
- Pancreatic and Hepatic Oncology Research
- Pituitary Gland Disorders and Treatments
- Parathyroid Disorders and Treatments
- COVID-19 epidemiological studies
- Systemic Sclerosis and Related Diseases
- Vaccine Coverage and Hesitancy
- Adrenal Hormones and Disorders
Chulabhorn Hospital
2022-2024
Due to the vaccine's short supply and efficacy of a single dose ChAdOx1 (AZD1222) vaccine, many governments delayed interval between prime boost from 4 8-12 weeks. However, waning immune response in this period is concern. This study evaluated durability, contributing factors anti-RBD antibody concentration, reactogenicities after AZD1222 vaccine Thai population.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals certain comorbidities may have a poor immune response require early booster vaccines. We aimed to assess the after two doses of ChAdOx1 nCoV-19 vaccine, at 84-day intervals, participants following comorbidities; diabetes mellitus; obesity; cardiovascular disease; chronic kidney rheumatological cirrhosis; hematological malignancy; or solid...
Background: Vaccines for SARS-CoV-2 have been critical preventing disease. Previous research showed patients with diabetes impaired immunity. This study aimed to determine the immunity coronavirus after CoronaVac by comparing type 2 (T2D) and healthcare workers (HCW). Materials methods: A prospective cohort evaluated immune responses safety two doses of in T2D HCW groups at Chulabhorn Hospital. The levels total antibodies against receptor-binding domain (anti-RBD) spike protein baseline 4...
Introduction Infection with SARS-CoV-2 virus may result in long COVID, a syndrome characterized by symptoms such as dyspnea, cardiac abnormalities, cognitive impairment, and fatigue. One potential explanation for these is hypocortisolism. Objective To evaluate the prevalence of hypocortisolism patients history COVID-19 pneumonia. Methods Cross-sectional study who were aged ≥18 years had 3-month radiography-confirmed Exclusion criteria included current or previous treatment glucocorticoids...
Abstract The ChAdOx1 nCoV-19 vaccine (AZD1222) was used in Thailand during the early outbreak of coronavirus disease 2019 (COVID-19). A previous study showed a low immune response diabetes patients after first dose AZD1222 vaccine. Furthermore, humoral responses second vaccination were inconsistent. This evaluated immunogenicity following and doses people with type 2 (T2D) compared general population Thailand. prospective, single-center cohort study. 59 adults T2D 118 age- sex-matched...